Myriad Genetics, Inc. (MYGN)
| Market Cap | 1.63B |
| Revenue (ttm) | 802.20M |
| Net Income (ttm) | -155.20M |
| Shares Out | 90.82M |
| EPS (ttm) | -1.78 |
| PE Ratio | n/a |
| Forward PE | 122.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,737,498 |
| Open | 20.04 |
| Previous Close | 21.96 |
| Day's Range | 16.86 - 20.06 |
| 52-Week Range | 16.00 - 29.30 |
| Beta | 1.92 |
| Analysts | Buy |
| Price Target | 28.18 (+56.64%) |
| Earnings Date | Nov 7, 2024 |
About MYGN
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or sus... [Read more]
Financial Performance
In 2023, Myriad Genetics's revenue was $753.20 million, an increase of 11.03% compared to the previous year's $678.40 million. Losses were -$263.30 million, 135.1% more than in 2022.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for MYGN stock is "Buy." The 12-month stock price forecast is $28.18, which is an increase of 56.64% from the latest price.
News
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
SALT LAKE CITY, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its third quarter earnings conference call on Thur...
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
Myriad's MyRisk® test is the first hereditary cancer test integrated into Flatiron's OncoEMR® SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genet...
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
SALT LAKE CITY, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a series of ongoing research collaborations...
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
SALT LAKE CITY and FREMONT, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Ultima Genomics, Inc., a developer ...
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
SALT LAKE CITY, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark...
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will participate in two u...
Myriad Genetics, Inc. (MYGN) Q2 2024 Earnings Call Transcript
Myriad Genetics, Inc. (NASDAQ:MYGN) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Matt Scalo - Senior Vice President-Investor Relations Paul Diaz - President & Chief...
EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT® GENOMIC TEST FROM MYRIAD GENETICS
EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT ® GENOMIC TEST FROM MYRIAD GENETICS
Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
SALT LAKE CITY, July 31, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Jennifer Fox as Chief Leg...
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) toda...
Myriad Genetics Earns 2024 Great Place To Work® Certification™
SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has received the Great Place To Work Cert...
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affects Their Mental Health New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affe...
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine, an official jou...
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
VENLO, The Netherlands and SALT LAKE CITY, May 30, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a gl...
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators Molecular Residual Disease (MRD) study and multiple RiskScore st...
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
Myriad's Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1
Myriad Genetics, Inc. (MYGN) Q1 2024 Earnings Call Transcript
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Matthew Scalo - Senior Vice President of Investor Relations Paul Diaz - President and ...
Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA
Highlights: First quarter revenue of $202 million grew 12% year-over-year, driven by Prenatal ( 22%), Pharmacogenomics ( 21%), and Hereditary Cancer ( 16%). First quarter average revenue per test i...
Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
SALT LAKE CITY, May 07, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the reorganization of its European operatio...
Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
Management will also participate in four upcoming investor healthcare conferences Management will also participate in four upcoming investor healthcare conferences
Nearly Half of Americans Say They've Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
80% of people diagnosed with anxiety, depression report losing years or decades of time 80% of people diagnosed with anxiety, depression report losing years or decades of time
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Prenatal Diagnosis has published a s...
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing
Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight test Fewer patients were prescribed medications with gene-drug interactions after taking the GeneSight...
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Tradema...
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the U.S. Patent and Trademark Office...